From Psilocybin to Precision Medicine: The Evolution of 5-HT2A Agonist Therapy

 

Introduction: A Molecule That Changed Everything — And Why We're Just Getting Started

There's a certain irony in the story of psilocybin. For decades, it was dismissed as a countercultural relic — a compound associated with 1960s experimentation and little else. And yet, buried beneath that stigma was a molecule with a genuine ability to alter brain circuitry, reduce depressive symptoms, and do things that conventional antidepressants had never been able to accomplish.

Today, the neuroscience community isn't just revisiting psilocybin — it's using it as a launchpad. The real conversation in 2025 isn't about magic mushrooms. It's about what psilocybin revealed: that the 5-HT2A receptor — a specific branch of the brain's serotonin system — holds enormous therapeutic potential. And that if we can activate that receptor more precisely, with fewer side effects and greater control, we might finally crack open some of the most stubborn neurological and psychiatric conditions of our time.

This is the story of that evolution — from a psychedelic compound that sparked curiosity to a new class of precision-engineered drugs called 5-HT2A agonists that are reshaping how we think about brain medicine. It's a story worth understanding, whether you're a clinician, a researcher, an investor, or simply someone who has watched a loved one cycle through antidepressant after antidepressant without relief.

 Part 1: Understanding the Foundation — What Is the Serotonin System, Really?

What Does Serotonin Actually Do in the Brain?

Most people know serotonin as the "feel-good chemical." That's not wrong, but it's wildly incomplete — like describing the internet as "a way to send emails." Serotonin (technically known as 5-hydroxytryptamine, or 5-HT) is one of the brain's most versatile neurotransmitters. It influences mood, yes — but also memory, cognition, appetite, impulse control, sleep, pain perception, and even seizure activity.

What makes the serotonin system particularly complex — and particularly important to understand for the purposes of this article — is that it doesn't operate through a single receptor. It operates through at least 14 distinct receptor subtypes, each distributed differently across the brain and spinal cord, each producing different downstream effects when activated.

Think of serotonin like a master key. But the locks it opens — the receptors — are not all the same. Some of those locks, when opened, produce therapeutic benefits. Others, when opened, produce side effects, cardiac risks, or unwanted psychedelic experiences. The entire challenge of modern serotonin-based drug development comes down to one question: can we make keys that only open the right locks?

Why Have Traditional Serotonin Drugs Been So Blunt?

 

The dominant serotonin drugs of the past 40 years — selective serotonin reuptake inhibitors (SSRIs) like fluoxetine, sertraline, and escitalopram — don't actually target receptors at all. They work at the level of the synapse, blocking the reabsorption of serotonin so more of it remains available in the space between neurons. It's a blunt, system-wide approach: flood the entire serotonin environment and hope the brain self-corrects.

For many patients, it works — partially. But the limitations are well-documented. SSRIs take weeks to show effects. They're associated with sexual dysfunction, weight gain, sleep disruption, and emotional blunting. And for a significant portion of patients — estimates range from 30 to 50 percent — they don't achieve full remission at all. These patients are classified as having treatment-resistant depression, and they're the ones who end up cycling through multiple drugs, augmentation strategies, or more invasive interventions like electroconvulsive therapy or ketamine infusions.

The problem with SSRIs isn't that serotonin was the wrong target. It's that flooding the entire serotonin system — all 14 receptor subtypes — is the wrong strategy. Precision was always the missing piece.

 Part 2: Psilocybin Enters the Conversation — What Did It Teach Us?

How Did Psilocybin Become a Scientific Tool?

Psilocybin is the naturally occurring psychoactive compound found in certain species of mushrooms. In the body, it's rapidly converted to psilocin, which binds with high affinity to the 5-HT2A receptor — one of the most psychiatrically relevant serotonin receptor subtypes in the brain.

When Johns Hopkins, NYU, and Imperial College London began publishing controlled clinical trial data on psilocybin in the 2010s, the results were striking. Patients with major depressive disorder who had failed multiple prior treatments showed rapid, significant, and often lasting reductions in symptoms after just one or two guided psilocybin sessions. In some studies, the effect sizes were substantially larger than anything seen with conventional antidepressants.

But what made psilocybin scientifically valuable wasn't just that it worked. It was how it worked — and what that told us about the brain.

What Does Psilocybin Actually Do to the Brain?

Psilocybin, through its conversion to psilocin and subsequent activation of the 5-HT2A receptor, produces what neuroscientists call "neuroplasticity" — the brain's ability to rewire and form new connections. Specifically, it appears to disrupt entrenched patterns of neural activity in circuits associated with rumination, negative self-referential thinking, and the rigid cognitive loops that characterize depression.

Think of it this way: chronic depression is partly a problem of the brain getting stuck in a groove — replaying the same negative thought patterns over and over. Psilocybin, at a biological level, seems to temporarily loosen that groove, creating a window of increased cognitive and emotional flexibility. Patients describe gaining new perspective on their lives. Neuroimaging shows reduced hyperactivity in the default mode network — a region associated with self-referential rumination.

This was a revelation. For the first time, researchers had compelling evidence that activating the 5-HT2A receptor could do something SSRIs couldn't: produce rapid, lasting changes in brain circuit connectivity, not just incremental shifts in neurotransmitter availability.

So Why Isn't Psilocybin the Answer?

Here's where the story gets more nuanced — and where the transition to precision medicine begins.

Psilocybin is a powerful molecule, but it is emphatically not a precise one. It activates not only 5-HT2A receptors but also 5-HT2B receptors — and 5-HT2B activation is associated with cardiac valvulopathy (heart valve damage) and other adverse effects that make chronic use clinically unacceptable. This is not a minor footnote. It's a fundamental barrier to developing psilocybin into a conventional, repeatable pharmaceutical.

Beyond cardiac concerns, psilocybin produces profound hallucinogenic experiences — the "trip" — which requires supervised clinical settings, trained therapists, extended session times, and significant infrastructure. This makes it expensive, logistically complex, and inaccessible at scale. A treatment that requires someone to spend eight hours in a clinical facility under observation simply cannot reach the majority of patients who need it.

There are also questions about tolerance, psychological preparedness, and what happens in patients with a history of psychosis or certain psychiatric vulnerabilities.

Psilocybin opened the door to 5-HT2A agonist therapy as a therapeutic strategy. But it also made the limitations of that approach — in its unrefined form — very clear. The question became: can we preserve the mechanism, strip away the problems, and build something better?

 Part 3: The Science of Precision — Engineering the Next Generation of 5-HT2A Agonists

What Makes a "Next-Generation" 5-HT2A Agonist Different?

The phrase "next-generation" gets used loosely in drug development, but in the context of 5-HT2A agonist therapy, it has a very specific meaning. A next-generation compound must accomplish several things that psilocybin cannot:

• Receptor selectivity: It must activate 5-HT2A and/or 5-HT2C receptors without activating 5-HT2B, eliminating the cardiac safety concern that makes psilocybin unsuitable for chronic use.
• Reduced or absent psychedelic effect: It must achieve the therapeutic downstream effects of 5-HT2A activation — neuroplasticity, circuit reset, mood stabilization — without producing hallucinogenic experiences that require supervised administration.
• Chronic dosing viability: It must be safe and effective for repeated, long-term use — which most psychiatric and neurological conditions require.
• Improved side effect profile: It must avoid the weight gain, sleep disruption, and other effects associated with SSRIs and broad-spectrum agents.

Achieving all of this simultaneously is an exceptionally difficult medicinal chemistry challenge. It requires a deep understanding of how the 5-HT2A receptor's molecular structure produces different effects depending on how it's activated — a concept known as biased agonism or functional selectivity.

What Is Biased Agonism and Why Does It Matter?

Here's an important concept that often gets glossed over in popular science coverage, but is central to understanding why next-generation 5-HT2A agonists are technically distinct from psilocybin.

When a drug binds to a G-protein coupled receptor like 5-HT2A, it doesn't just flip a simple on/off switch. The receptor can signal through multiple downstream pathways simultaneously. Depending on the exact shape of the molecule that binds to it, the receptor will favor different signaling cascades — some of which produce therapeutic effects, others of which produce side effects or hallucinogenic activity.

A biased agonist is a molecule engineered to activate the receptor in a way that preferentially engages the therapeutic signaling pathway while minimizing activity through pathways linked to unwanted effects. This requires extraordinary precision at the molecular level — understanding not just which receptor to target, but how to bind to it, at what angle, with what chemical features.

This is precisely the kind of medicinal chemistry work that defines advanced 5-HT2A agonist drug development. Companies working in this space aren't just synthesizing analogues of psilocybin. They're building entirely new chemical entities with carefully designed receptor interaction profiles.

What Conditions Are Next-Generation 5-HT2A Agonists Being Developed For?

The scope of potential applications is broader than most people realize. Because the serotonin system — particularly the 5-HT2A and 5-HT2C subtypes — is involved in such a wide range of brain functions, precision agonist therapy has therapeutic potential across multiple disease areas:

Major Depressive Disorder (MDD)
This is where the psilocybin data created the most momentum. Patients with SSRI-resistant MDD are a massive underserved population. Next-generation 5-HT2A agonists aim to replicate psilocybin's circuit-resetting mechanism without the hallucinogenic experience or clinical infrastructure requirements.

Drug-Resistant Epilepsy
This is a less intuitive application but a scientifically compelling one. Research has shown that 5-HT2C receptor activation can modulate seizure thresholds. In drug-resistant epilepsy — where seizures persist despite multiple antiseizure medications — a selective 5-HT2C agonist represents a genuinely novel mechanism of action that doesn't overlap with existing drug targets.

Prader-Willi Syndrome (PWS)
PWS is a rare genetic disorder defined by relentless hyperphagia — an insatiable, compulsive drive to eat that can lead to life-threatening obesity. The 5-HT2C receptor plays a known role in appetite regulation and impulse control, making it a rational target. What makes this particularly interesting from a drug development perspective is that a 5-HT2C agonist could simultaneously address the hyperphagia, the anxiety, and the compulsive behavioral patterns that characterize PWS — addressing multiple dimensions of the condition with a single mechanism.

Behavioral and Psychological Symptoms of Dementia (BPSD)
Patients with Alzheimer's disease and other dementias frequently exhibit what's called the HIDA domain: hyperactivity, impulsivity, irritability, disinhibition, aggression, and agitation. These symptoms are currently managed with atypical antipsychotics — drugs that carry serious risks, including increased mortality in elderly patients. A selective 5-HT2C agonist that could reduce impulsivity without the cardiovascular or sedative risks of antipsychotics would represent a meaningful advance.

Substance Use Disorders and Binge Eating
The 5-HT2C receptor's role in reward modulation and impulse control has implications for addiction medicine as well. Preclinical and emerging clinical data suggest that 5-HT2C agonism can reduce craving and compulsive consumption behaviors relevant to opioid use disorder, cocaine use, nicotine dependence, and binge eating disorder.

Parkinson's Disease — The Impulsivity Problem
Dopaminergic drugs — the mainstay of Parkinson's treatment — can paradoxically worsen impulsivity in some patients. A 5-HT2C agonist that addresses impulsivity without interfering with dopamine pathways could fill a real gap in Parkinson's disease management.

 Part 4: Comparing the Approaches — Psilocybin vs. Next-Generation 5-HT2A Agonist Therapy

How Do the Two Approaches Stack Up Against Each Other?

Understanding the distinction between psilocybin-assisted therapy and next-generation 5-HT2A agonist therapy is critical — they are sometimes conflated in media coverage, but they are meaningfully different in their clinical application, scalability, and risk profile.

Feature	Psilocybin	Next-Gen 5-HT2A/5-HT2C Agonists
Receptor target	5-HT2A, 5-HT2B, other subtypes	Selective 5-HT2A and/or 5-HT2C
5-HT2B activity	Yes — cardiac safety concern	Engineered out — no 5-HT2B
Psychedelic experience	Significant — requires supervision	Reduced or absent
Administration setting	Specialized clinical facility	Outpatient / standard clinical
Dosing frequency	Single or infrequent sessions	Designed for chronic use
Scalability	Low — infrastructure-intensive	High — conventional prescribing
Regulatory pathway	Complicated by schedule status	Standard drug approval pathway
Chronic use viability	Not established	Core design requirement

This comparison illustrates why precision engineering matters. Psilocybin's clinical value lies in its proof-of-concept — it demonstrated, powerfully, that 5-HT2A activation can produce profound and lasting therapeutic effects. But the drug itself is too blunt, too unpredictable in its receptor profile, and too logistically demanding to serve as the solution at scale. Next-generation 5-HT2A agonist therapy takes the insight psilocybin provided and operationalizes it into a form that can actually reach patients in a clinical setting.

What Are the Advantages of Next-Generation Agonist Therapy?

 

The advantages are substantial:

• Safety by design: Removing 5-HT2B activity from the receptor profile eliminates the cardiac valvulopathy concern that shadows psilocybin-derived compounds.
• Accessibility: When a treatment doesn't require an eight-hour supervised session in a clinical setting, it becomes available to far more patients — including those in rural areas, those without access to specialized psychedelic therapy centers, and those who simply cannot afford the cost of psychedelic-assisted therapy programs.
• Chronic disease management: Most neurological and psychiatric conditions are chronic. They require ongoing management, not a one-time intervention. A drug designed for daily or regular use fits the actual reality of these diseases far better than an occasional high-dose psychedelic session.
• Specificity of effect: By targeting specific receptor subtypes with precision, next-generation compounds can be tailored to specific disease mechanisms — a 5-HT2C agonist for appetite and impulsivity, a 5-HT2A agonist for depressive circuit disruption, or a dual 5-HT2A/2C agonist when both mechanisms are therapeutically relevant.

What Are the Challenges That Still Need to Be Solved?

 

This field is not without its complexity. Several challenges remain:

• Clinical trial design: Measuring outcomes for conditions like MDD, epilepsy, and PWS requires carefully validated endpoints. For newer compounds without established clinical history, trial design is a significant methodological challenge.
• Regulatory navigation: While next-generation 5-HT2A agonists are not scheduled substances (unlike psilocybin), they still require rigorous safety and efficacy data, particularly given their mechanism's proximity to psychedelic compounds.
• Patient selection: Not all patients with a given diagnosis will respond to serotonergic mechanisms equally. Understanding which patients are most likely to benefit from 5-HT2A or 5-HT2C agonist therapy — and developing biomarkers to identify them — is ongoing work.
• Long-term safety data: Because these are novel chemical entities, long-term safety profiles are still being established. Chronic use safety is particularly important for conditions like PWS, which requires lifetime management.
•  

 

 Part 5: The Bigger Picture — What Does This Mean for the Future of Psychiatry and Neurology?

Is the Era of One-Size-Fits-All Psychopharmacology Ending?

In a word: yes — and it's long overdue.

The history of psychiatric medication is largely a history of serendipity. Lithium's mood-stabilizing properties were discovered accidentally. The antidepressant effects of iproniazid were noticed when it was being tested as a tuberculosis drug. Chlorpromazine's antipsychotic properties emerged from a surgical anesthetic program. These discoveries were genuinely important — but they weren't designed. They were found.

For decades, the field iterated on these accidental discoveries, creating successive generations of drugs that were cleaner, safer, and better-tolerated, but still operating within the same broad mechanisms. SSRIs improved on tricyclic antidepressants. Atypical antipsychotics improved on first-generation antipsychotics. But the underlying logic — block a reuptake transporter here, antagonize a receptor there — remained largely empirical rather than mechanistic.

What's changing now is the approach. Next-generation 5-HT2A agonist therapy represents a deliberate, hypothesis-driven strategy grounded in a specific understanding of brain circuit dysfunction. The goal isn't to flood a neurotransmitter system and wait. It's to engage a defined receptor, in a defined way, to produce a defined physiological outcome in a defined patient population. That is the definition of precision medicine — and it's precisely what this field is moving toward.

How Does This Relate to the Broader Trend of Personalized Neuropsychiatry?

Personalized medicine in oncology has become standard practice — tumor genomics guide drug selection, biomarkers predict response, and treatment is tailored to the molecular profile of each patient's disease. Psychiatry and neurology are moving, slowly but deliberately, in the same direction.

For 5-HT2A agonist therapy specifically, this means identifying which patients — based on their neuroimaging profiles, genetic variants in serotonin receptor genes, or clinical phenotype — are most likely to respond to 5-HT2A or 5-HT2C modulation. It means designing clinical trials that enrich for responders rather than treating all patients with a diagnosis as interchangeable. And it means thinking about the receptor system as a sophisticated biological tool, not a blunt pharmacological hammer.

This is still early-stage work. But the trajectory is clear — and the scientific infrastructure being built around precision serotonin agonism today will form the basis of neuropsychiatric prescribing a decade from now.

What Role Do Drug-Resistant Populations Play in Advancing This Field?

Drug-resistant populations — patients who have failed multiple treatments — are not just an underserved market. They are the scientific proving ground for novel mechanisms. When a new compound works in a patient who has failed six prior medications, it tells you something important: the mechanism is genuinely different. It's not just another SSRI wrapped in a new molecule.

This is one reason why next-generation 5-HT2A agonist programs are so scientifically significant even at early clinical stages. If these compounds demonstrate efficacy in SSRI-resistant depression, in drug-resistant epilepsy, or in PWS patients who have no effective pharmaceutical options — that data creates an entirely new therapeutic category, not just an incremental improvement on existing drugs.

 Part 6: Common Misconceptions Worth Addressing

Is This Just About Making Legal Psychedelics?

This is perhaps the most persistent misunderstanding in public coverage of this field. Next-generation 5-HT2A agonists are not psychedelics. They are not reformulated versions of psilocybin. They are novel chemical entities, designed from the ground up to activate specific receptor pathways without producing hallucinogenic experiences.

The connection to psilocybin is historical and mechanistic — psilocybin's clinical data motivated the scientific investment in 5-HT2A agonist therapy, and psilocybin's mechanism of action at the 5-HT2A receptor informed the molecular design of next-generation compounds. But describing next-gen agonists as "legal psychedelics" is like describing a precision surgical robot as a "kitchen knife" because both involve cutting.

Are SSRIs Being Abandoned?

No — and that framing sets up a false opposition. SSRIs remain appropriate first-line treatments for many patients, particularly those with mild to moderate depression who haven't tried serotonergic therapies. Next-generation 5-HT2A agonist therapy is not positioned as a replacement for SSRIs across the board. It's positioned as a more targeted alternative — particularly for the substantial minority of patients who don't respond adequately to SSRIs, and for conditions where SSRI mechanisms are simply not relevant.

Does "Precision" Mean These Drugs Are Safer for Everyone?

Precision refers to receptor selectivity — the ability to activate specific serotonin receptor subtypes without activating others. This does improve the safety profile in meaningful ways, particularly around cardiac risk (by eliminating 5-HT2B activity) and around side effects related to non-target receptor activity. But "more precise" does not mean "universally safe." As with any novel pharmacological class, long-term safety in diverse patient populations will be established through clinical trials, post-market surveillance, and real-world use over time.

 Frequently Asked Questions

What is the difference between psilocybin and a 5-HT2A agonist drug?

Psilocybin is a naturally occurring psychedelic compound that activates multiple serotonin receptors, including 5-HT2A, 5-HT2B, and others. A next-generation 5-HT2A agonist is a synthetically engineered drug designed to selectively activate only specific serotonin receptor subtypes — particularly 5-HT2A and/or 5-HT2C — while avoiding 5-HT2B, which is linked to cardiac risks. This selectivity is what makes next-gen agonists safer and more viable for chronic use compared to psilocybin.

Why hasn't psilocybin been developed into a standard pharmaceutical?

Several factors create barriers: psilocybin's schedule I legal status in the US and Canada (outside specific research exemptions), its activation of 5-HT2B receptors which creates cardiac safety concerns for chronic use, its production of profound hallucinogenic experiences requiring supervised clinical settings, and the logistical challenges of delivering therapy that takes 6–8 hours per session. These barriers don't eliminate psilocybin's value as a research tool and therapeutic agent in its own right — but they limit its scalability.

What is the 5-HT2C receptor, and why is it important?

The 5-HT2C receptor is a serotonin receptor subtype particularly concentrated in the hypothalamus, limbic system, and areas of the brain responsible for appetite regulation, impulse control, and emotional processing. Unlike 5-HT2A, which is most relevant to mood and cognitive circuit modulation, 5-HT2C plays a central role in satiety, reward, and behavioral inhibition. This makes it a compelling target for conditions involving impulsivity (Parkinson's, BPSD), compulsive eating (Prader-Willi Syndrome), substance use disorders, and certain forms of anxiety.

Could 5-HT2A agonist therapy eventually replace antidepressants?

Not wholesale — but for specific patient populations, particularly those with treatment-resistant depression or those who experience significant side effects from SSRIs, next-generation 5-HT2A agonist therapy has the potential to become a first-line option. The field is still in clinical development, and regulatory approvals will shape prescribing norms. What's more likely, at least in the near term, is that these compounds become important options within a broader toolkit — used when SSRIs have failed, when the mechanism is particularly well-suited to a patient's specific neurobiological profile, or when the condition itself is not responsive to conventional serotonergic approaches.

Is 5-HT2A agonist therapy available to patients today in the US or Canada?

As of 2025, next-generation selective 5-HT2A and 5-HT2C agonist drugs are primarily in clinical development — Phase 1 and Phase 2 trials are active in various programs. They are not yet available as approved medications through standard prescribing. Psilocybin itself remains a Schedule I substance in the US at the federal level, though it has received Breakthrough Therapy designation from the FDA for depression, and Canada has allowed limited therapeutic access in specific clinical contexts. Patients interested in participating in trials can explore options through clinical trial registries.

How long before these drugs reach the market?

Drug development timelines are notoriously difficult to predict, particularly in CNS — the most challenging therapeutic area in terms of trial design, endpoint validation, and regulatory requirements. Programs currently in Phase 2 clinical trials, if they generate positive data, could reasonably progress to Phase 3 and NDA/NDS filing within the next four to seven years. The exact timeline depends on trial results, regulatory interactions, and development decisions made at each stage.

Does the psychedelic mechanism matter if the drug doesn't make you hallucinate?

Yes — and this is one of the more interesting scientific questions in the field. Researchers are still investigating whether the hallucinogenic experience itself contributes to the therapeutic benefit of psilocybin, or whether it's simply a byproduct of receptor activation that can be separated from the mechanism that produces clinical improvement. If the therapeutic effect is entirely downstream of receptor activation (and therefore separable from the perceptual experience), next-generation agonists that achieve the same receptor pharmacology without the hallucinogenic effect should produce equivalent or superior outcomes. Early data from biased agonism research suggests this separation is achievable — but it remains an active area of investigation.

 Conclusion: What Psilocybin Started, Precision Science Is Finishing

Psilocybin didn't create the opportunity for next-generation 5-HT2A agonist therapy — it revealed it. It showed the neuroscience community that the 5-HT2A receptor was a viable target for some of the most resistant conditions in psychiatry and neurology. It demonstrated that rapid, durable changes in brain circuit connectivity were possible through serotonergic mechanisms. And it created the scientific and cultural momentum that justified the investment now going into precision-engineered alternatives.

What comes next is harder, more rigorous, and more consequential. Engineering a molecule that selectively activates specific serotonin receptor subtypes, avoids cardiac liability, produces therapeutic effects without hallucinogenic side effects, and is safe for chronic use is not a small task. It's precisely the kind of challenge that separates the next generation of CNS drugs from everything that came before.

Key Takeaways

• Serotonin is not one signal — it's a system of at least 14 distinct receptor subtypes, each with different functional roles in the brain. Effective drug development requires targeting the right subtypes, not flooding the system.
• Psilocybin proved the concept: 5-HT2A receptor activation can produce rapid, lasting changes in brain circuit connectivity, with clinical effects that conventional antidepressants cannot match. But psilocybin's lack of receptor selectivity — particularly its 5-HT2B activity — creates barriers to safe, scalable pharmaceutical development.
• Next-generation 5-HT2A and 5-HT2C agonists are designed from the ground up to preserve the therapeutic mechanism while eliminating the problems — offering receptor selectivity, chronic use viability, and standard clinical delivery.
• The therapeutic scope is broader than depression: Drug-resistant epilepsy, Prader-Willi Syndrome, treatment-resistant MDD, behavioral symptoms of dementia, impulse control in Parkinson's, and substance use disorders all have biological rationale for 5-HT2A/5-HT2C agonist therapy.
• This is precision medicine applied to the brain — a deliberate, hypothesis-driven approach to CNS drug development that represents a genuine paradigm shift from the empirical, serendipity-driven models of the past.
• The era of blunt psychiatric pharmacology is ending. What replaces it — precision serotonin agonism among other innovations — will be defined by the science being done right now.

The path from a psychedelic mushroom compound to a precision-engineered brain medicine is not a straight one. But it's a path that's being walked, deliberately, by some of the most capable neuroscientists and drug developers in the world. And the patients waiting on the other end of that path — the one-third of epilepsy patients whose seizures don't respond to any available drug, the MDD patients who have tried every antidepressant and still can't function, the children with Prader-Willi Syndrome whose families watch around the clock — have every reason to be cautiously hopeful that precision agonist therapy will be worth the wait.